A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 30, 2011, Pages 12461-12466

  Beltran, Elena ^a   Fresquet, Vicente ^a   Martinez Useros, Javier ^a   Richter Larrea, Jose A ^a   Sagardoy, Ainara ^a   Sesma, Izaskun ^a   Almada, Luciana L ^b   Montes Moreno, Santiago ^c   Siebert, Reiner ^d   Gesk, Stefan ^d   Calasanz, Maria J ^e   Malumbres, Raquel ^a   Rieger, Melissa ^a   Prosper, Felipe ^a,f   Lossos, Izidore S ^g   Piris, Miguel Angel ^c   Fernandez Zapico, Martin E ^b   Martinez Climent, Jose A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b MAYO CLINIC   (United States)

^c Centro Nacional de Investigations Oncológicas   (Spain)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF NAVARRA   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g UNIVERSITY OF MIAMI   (United States)

Author keywords

ABT 737; Cyclin D1 inhibitor drugs; Mouse model of MCL; Oncogene addiction; Targeted therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CYCLIN D1; DOXYCYCLINE; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CELL PROLIFERATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; DISEASE MODELS, ANIMAL; GENE AMPLIFICATION; GENES, BCL-2; HUMANS; LYMPHOMA, MANTLE-CELL; MICE; NITROPHENOLS; PIPERAZINES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; MUS;

EID: 79961079532     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018941108     Document Type: Article

References (28)

1. Harris NL, et al. (2000) The World Health Organization classification of hematological malignancies: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193-207. (Pubitemid 30109108)
2. Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36:115-127. (Pubitemid 29214065)
3. Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 7:750-762. (Pubitemid 47463673)
4. Bodrug SE, et al. (1994) Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13:2124-2130. (Pubitemid 24139725)
5. Tagawa H, et al. (2005) Genome-wide array-based CGH for mantle cell lymphoma: Identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24: 1348-1358. (Pubitemid 40343115)
6. Stilgenbauer S, et al. (1999) Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 94:3262-3264. (Pubitemid 29512737)
7. Rubio-Moscardo F, et al. (2005) Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105:4445-4454. (Pubitemid 40720793)
8. Witzig TE (2005) Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23:6409-6414.
9. Dreyling M, Hiddemann W (2008) Dose-intense treatment of mantle cell lymphoma: Can durable remission be achieved? Curr Opin Oncol 20:487-494.
10. O'ConnorOA(2007)Mantle cell lymphoma: Identifyingnovelmolecular targets ingrowth and survival pathways. Hematology Am Soc Hematol Educ Program 2007:270-276.
11. Ghielmini M, Zucca E (2009) How I treat mantle cell lymphoma. Blood 114:1469-1476.
12. Klier M, et al. (2008) Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 22:2097-2105.
13. Oltersdorf T, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681. (Pubitemid 40825512)
14. Traggiai E, et al. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104-107. (Pubitemid 38451466)
15. Mestre-Escorihuela C, et al. (2007) Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109:271-280. (Pubitemid 46053067)
16. Pérez-Mancera PA, et al. (2005) Cancer development induced by graded expression of Snail in mice. Hum Mol Genet 14:3449-3461. (Pubitemid 41672128)
17. Kominami R, Niwa O (2006) Radiation carcinogenesis in mouse thymic lymphomas. Cancer Sci 97:575-581. (Pubitemid 44056604)
18. Khoury JD, et al. (2003) Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 199:90-97. (Pubitemid 36054733)
19. Beà S, et al. (1999) Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93:4365-4374. (Pubitemid 29279280)
20. Hernández L, et al. (2005) CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 65:2199-2206. (Pubitemid 40490128)
21. Quintanilla-Martinez L, et al. (2003) Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): Implications for pathogenesis. Blood 101:3181-3187. (Pubitemid 36858013)
22. Wang G, et al. (2006) Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 49:6139-6142. (Pubitemid 44595187)
23. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547-566.
24. Felsher DW (2003) Cancer revoked: Oncogenes as therapeutic targets. Nat Rev Cancer 3:375-380.
25. Ahmed KM, Fan M, Nantajit D, Cao N, Li JJ (2008) Cyclin D1 in low-dose radiation-induced adaptive resistance. Oncogene 27:6738-6748.
26. Roué G, Pichereau V, Lincet H, Colomer D, Sola B (2008) Cyclin D1 mediates resistance to apoptosis through up-regulation of molecular chaperones and consequent redistribution of cell death regulators. Oncogene 27:4909-4920.
27. Bienvenu F, et al. (2010) Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 463:374-378.
28. Richter-Larrea JA, et al. (2010) Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116:2531-2542.